Peake M F, Perkins P, Elston D M, Older S A, Vinson R P
Department of Medicine, Brooke Army Medical Center, Fort Sam Houston, Texas, USA.
Cutis. 1998 Aug;62(2):89-93.
We report the case of a woman from the Bahamas who presented with many of the classic manifestations of dermatomyositis. She responded well to initial therapy, which included oral corticosteroids, low-dosage methotrexate, and hydroxychloroquine. The cutaneous component of her disease flared dramatically months later, and progressed despite aggressive therapy with the higher dosages of the same medications. Therapy with intravenous immunoglobulin (IVIG) was initiated and the patient stopped forming new cutaneous ulcers within 1 to 2 weeks. Theories about the mechanism of action of IVIG, and practical guidelines for its use in treating patients with dermatomyositis, are briefly reviewed.
我们报告了一例来自巴哈马群岛的女性病例,该患者出现了许多皮肌炎的典型表现。她对初始治疗反应良好,初始治疗包括口服皮质类固醇、低剂量甲氨蝶呤和羟氯喹。数月后,她疾病的皮肤症状急剧加重,尽管加大了相同药物的剂量进行积极治疗,病情仍在进展。于是开始采用静脉注射免疫球蛋白(IVIG)治疗,患者在1至2周内停止形成新的皮肤溃疡。本文简要回顾了关于IVIG作用机制的理论,以及其用于治疗皮肌炎患者的实用指南。